PMV Pharmaceuticals, Inc.
PMVP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001699382
No open-market purchases or sales by PMV Pharmaceuticals, Inc. insiders were filed in the last 90 days; 64 institutions reported holding it in 13F filings for Q3 2026, worth $94.4M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:15 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2026 | Mar 3, 2025 | Feb 29, 2024 | Mar 1, 2023 | Mar 1, 2022 |
| Operating expenses | $86.2M | $85.4M | $80.1M | $77.0M | $58.3M |
| Research and development | $69.9M | $58.5M | $55.9M | $52.0M | $36.5M |
| Selling, general and administrative | $16.3M | $26.9M | $24.2M | $25.1M | $21.8M |
| Operating income | -$86.2M | -$85.4M | -$80.1M | -$77.0M | -$58.3M |
| Income tax | -$2.17M | -$16.1M | $2.00K | -$9.00K | $23.0K |
| Net income | -$77.7M | -$58.7M | -$69.0M | -$73.3M | -$57.8M |
| EPS, basic | $-1.48 | $-1.14 | $-1.44 | $-1.61 | – |
| EPS, diluted | $-1.48 | $-1.14 | $-1.44 | $-1.61 | – |
| Weighted shares, basic | 52.5M | 51.6M | 48.0M | 45.6M | – |
| Weighted shares, diluted | 52.5M | 51.6M | 48.0M | 45.6M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2026 | Mar 3, 2025 | Feb 29, 2024 | Mar 1, 2023 | Mar 1, 2022 |
| Cash and equivalents | $38.0M | $40.9M | $37.7M | $108.3M | $172.5M |
| Short-term investments | $75.0M | $128.6M | $165.4M | $132.8M | $124.7M |
| Total current assets | $115.2M | $175.7M | $207.4M | $247.0M | $301.3M |
| Property, plant and equipment | $237.0K | $409.0K | $10.7M | $11.0M | $3.09M |
| Total assets | $116.6M | $191.3M | $252.2M | $270.3M | $331.6M |
| Accounts payable | $3.15M | $6.58M | $3.24M | $3.00M | $3.19M |
| Total current liabilities | $11.4M | $14.4M | $14.0M | $10.8M | $12.2M |
| Total liabilities | $11.8M | $15.2M | $26.5M | $24.3M | $23.0M |
| Shareholders' equity | $104.7M | $176.1M | $225.7M | $246.0M | $308.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2026 | Mar 3, 2025 | Feb 29, 2024 | Mar 1, 2023 | Mar 1, 2022 |
| Operating cash flow | -$73.6M | -$51.3M | -$55.7M | -$63.8M | -$46.6M |
| Capital expenditures | $29.0K | $655.0K | $962.0K | $7.98M | $1.35M |
| Free cash flow | -$73.6M | -$51.9M | -$56.6M | -$71.7M | -$47.9M |
| Stock-based compensation | $5.92M | $8.87M | $12.4M | $10.2M | $5.34M |
| Investing cash flow | $70.2M | $53.4M | -$50.5M | -$1.37M | -$143.6M |
| Financing cash flow | $505.0K | $313.0K | $35.6M | $958.0K | $2.02M |
| Net change in cash | -$2.89M | $2.35M | -$70.6M | -$64.2M | -$188.1M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 10, 2026 | 75.5M | +42.0% | SEC |
| Aug 14, 2026 | 53.5M | +0.9% | SEC |
| May 12, 2026 | 53.3M | +2.7% | SEC |
| Mar 3, 2026 | 53.3M | +2.7% | SEC |
| Nov 12, 2025 | 53.2M | +2.8% | SEC |
| Aug 7, 2025 | 53.0M | +2.9% | SEC |
| May 9, 2025 | 52.0M | +1.0% | SEC |
| Mar 3, 2025 | 51.9M | +1.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.